Glecaprevir/pibrentasvir for the Treatment of Chronic Hepatitis C: Design, Development, and Place in Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2019 Sep 20

PMID 31534310

Citations 14

Authors

Thomas G Cotter

Donald M Jensen

Affiliations

Soon will be listed here.

Abstract

Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the existing shortcomings in the DAA therapy spectrum. This combination has proven to be a highly efficacious pan-genotypic DAA with a high barrier to resistance as a once-daily, all-oral medication. This review explores the design and development of glecaprevir and pibrentasvir, its place in current HCV management in the midst of a myriad of DAA therapy options, and also remaining challenges.

Citing Articles

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs).

Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, La Mantia C Viruses. 2025; 17(2).

PMID: 40006918 PMC: 11860415. DOI: 10.3390/v17020163.

Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.

Broni E, Ashley C, Adams J, Manu H, Aikins E, Okom M Int J Mol Sci. 2023; 24(7).

PMID: 37047270 PMC: 10094735. DOI: 10.3390/ijms24076298.

Viral proteases as therapeutic targets.

Majerova T, Konvalinka J Mol Aspects Med. 2022; 88:101159.

PMID: 36459838 PMC: 9706241. DOI: 10.1016/j.mam.2022.101159.

A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.

Ramirez-Sanchez C, Kozuch J, Shah M, Berumen J, Mekeel K, Schnickel G Open Forum Infect Dis. 2022; 9(11):ofac550.

PMID: 36420058 PMC: 9679803. DOI: 10.1093/ofid/ofac550.

Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.

Chadha N, Turner A, Sterling R J Viral Hepat. 2022; 30(1):73-78.

PMID: 36301045 PMC: 10091705. DOI: 10.1111/jvh.13763.

References

Asselah T, Kowdley K, Zadeikis N, Wang S, Hassanein T, Horsmans Y . Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017; 16(3):417-426. DOI: 10.1016/j.cgh.2017.09.027. View

. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

Sievert W, Altraif I, Razavi H, Abdo A, Ahmed E, AlOmair A . A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 Suppl 2:61-80. DOI: 10.1111/j.1478-3231.2011.02540.x. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Belli L, Perricone G, Adam R, Cortesi P, Strazzabosco M, Facchetti R . Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018; 69(4):810-817. DOI: 10.1016/j.jhep.2018.06.010. View

Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C . Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2017; 67(4):1253-1260. PMC: 5901397. DOI: 10.1002/hep.29671. View

Zeuzem S, Foster G, Wang S, Asatryan A, Gane E, Feld J . Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018; 378(4):354-369. DOI: 10.1056/NEJMoa1702417. View

Kwo P, Poordad F, Asatryan A, Wang S, Wyles D, Hassanein T . Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017; 67(2):263-271. DOI: 10.1016/j.jhep.2017.03.039. View

Rockstroh J, Lacombe K, Viani R, Orkin C, Wyles D, Luetkemeyer A . Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018; 67(7):1010-1017. PMC: 6137115. DOI: 10.1093/cid/ciy220. View

10.

Honda M, Ping L, Rijnbrand R, Amphlett E, Clarke B, Rowlands D . Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology. 1996; 222(1):31-42. DOI: 10.1006/viro.1996.0395. View

11.

Gordon S, Muir A, Lim J, Pearlman B, Argo C, Ramani A . Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2014; 62(2):286-93. PMC: 4586075. DOI: 10.1016/j.jhep.2014.08.052. View

12.

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A . Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017; 377(15):1448-1455. DOI: 10.1056/NEJMoa1704053. View

13.

Lafferty L, Treloar C, Guthrie J, Chambers G, Butler T . Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison. J Viral Hepat. 2016; 24(2):111-116. DOI: 10.1111/jvh.12627. View

14.

Poordad F, Felizarta F, Asatryan A, Sulkowski M, Reindollar R, Landis C . Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017; 66(2):389-397. PMC: 5573922. DOI: 10.1002/hep.29081. View

15.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

16.

Gao M . Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013; 3(5):514-20. DOI: 10.1016/j.coviro.2013.06.014. View

17.

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View

18.

Simmonds P . The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013; 369:1-15. DOI: 10.1007/978-3-642-27340-7_1. View

19.

Uemura H, Uchida Y, Kouyama J, Naiki K, Tsuji S, Sugawara K . NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019; 54(5):459-470. DOI: 10.1007/s00535-018-01543-9. View

20.

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng T, Reisch T . Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153825. DOI: 10.1128/AAC.01249-18. View